Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors
Chenyue Zhang, Haiyong Wang
Topics & Concepts
MedicineDocetaxelNivolumabErlotinibLung cancerImmunotherapyAfatinibInternal medicineOncologyCD8CancerImmune systemImmunologyEpidermal growth factor receptorCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies